Additional file 1 of Diverging effects of tumor necrosis factor inhibitors and conventional synthetic disease-modifying antirheumatic drugs on immunosenescence and inflammageing in rheumatoid arthritis: a cross-sectional analysis

Supplementary Material 1: Supplementary Figure 1. Gating strategy of the flow cytometric analyses performed. According to phenotypic surface markers, CD45RA+CD28+ cells were characterized as naive T cells, CD45RA-CD28+ cells as memory T cells, CD45RA-CD28- cells as effector T cells, and CD45RA+CD28- cells as terminally-differentiated effector memory T cells re-expressing CD45RA (TEMRA). The proportions of IFNγ-/IL-17-expressing naive/effector/memory or TEMRA cells were determined (A). CD4+ RTE were identified by the expression of CD31, cells able to participate in IL-7-driven homeostatic proliferation by the expression of CD127. Proliferation of RTE or CD127+CD4+ T cells was determined by Ki67 (B). Th17 cells were determined by the expression of IL-17 and CCR6, Th1 cells by the expression of IFN and CXCR3 (C). Treg cells were defined as FoxP3+. Naturally occurring Treg (nTreg) cells were characterized by CD25 bright expression and CD127-negativity. Furthermore, the proportion of CD4+ T cells expressing IL-10 was determined (D). Supplementary Figure 2. Proportions of inflammatory cytokine secreting effector T cells in differently treated RA patients. Inflammatory cytokine secreting effector T cells in RA patients, treated with csDMARDs-only, TNFi-only or a combination of a TNFi and a csDMARD (methotrexate), compared to HC. csDMARD-only treated patients showed significantly reduced numbers of IFNγg CD4 , IFNγ CD8 (A) or IL-17 CD4 (B) effector T cells, compared to HC. TNFi-only treated patients instead displayed increased numbers of the respective effector T cells. Patients treated with the combination of a TNFi and methotrexate most closely resemble the HC. Bars represent median percentages and interquartile range. Kruskal-Wallis test was performed, followed by Dunn’s test to compare between the study populations.

Institutions

Publication Details

Journal
Figshare
Published
2025-01-01
DOI
https://doi.org/10.6084/m9.figshare.29133554
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Additional file 1 of Diverging effects of tumor necrosis factor inhibitors and conventional synthetic disease-modifying antirheumatic drugs on immunosenescence and inflammageing in rheumatoid arthritis: a cross-sectional analysis

Figshare
Rheumatoid Arthritis Research and Therapies
article

Additional file 1 of Diverging effects of tumor necrosis factor inhibitors and conventional synthetic disease-modifying antirheumatic drugs on immunosenescence and inflammageing in rheumatoid arthritis: a cross-sectional analysis

article en

Abstract

Supplementary Material 1: Supplementary Figure 1. Gating strategy of the flow cytometric analyses performed. According to phenotypic surface markers, CD45RA+CD28+ cells were characterized as naive T cells, CD45RA-CD28+ cells as memory T cells, CD45RA-CD28- cells as effector T cells, and CD45RA+CD28- cells as terminally-differentiated effector memory T cells re-expressing CD45RA (TEMRA). The proportions of IFNγ-/IL-17-expressing naive/effector/memory or TEMRA cells were determined (A). CD4+ RTE were identified by the expression of CD31, cells able to participate in IL-7-driven homeostatic proliferation by the expression of CD127. Proliferation of RTE or CD127+CD4+ T cells was determined by Ki67 (B). Th17 cells were determined by the expression of IL-17 and CCR6, Th1 cells by the expression of IFN and CXCR3 (C). Treg cells were defined as FoxP3+. Naturally occurring Treg (nTreg) cells were characterized by CD25 bright expression and CD127-negativity. Furthermore, the proportion of CD4+ T cells expressing IL-10 was determined (D). Supplementary Figure 2. Proportions of inflammatory cytokine secreting effector T cells in differently treated RA patients. Inflammatory cytokine secreting effector T cells in RA patients, treated with csDMARDs-only, TNFi-only or a combination of a TNFi and a csDMARD (methotrexate), compared to HC. csDMARD-only treated patients showed significantly reduced numbers of IFNγg CD4 , IFNγ CD8 (A) or IL-17 CD4 (B) effector T cells, compared to HC. TNFi-only treated patients instead displayed increased numbers of the respective effector T cells. Patients treated with the combination of a TNFi and methotrexate most closely resemble the HC. Bars represent median percentages and interquartile range. Kruskal-Wallis test was performed, followed by Dunn’s test to compare between the study populations.

Figshare
Innsbruck Medical University (AT), University of Würzburg (DE), Universität Greifswald (DE), Universitätsklinikum Würzburg (DE)
Good health and well-being
Openalex Percentile: Top 38%
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.